An agent which can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive product, improvement of bowel movement or the like and an agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like are provided. An intestinal tract function-improving agent, an immunoenhancing agent, a putrefactive product production-suppressing agent, a bowel movement-improving agent and an intestinal tract protection agent each containing a cyclodextrin as an active ingredient are provided. they can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive products, improvement of bowel movement or the like and the agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like. Using the agents as an active ingredient, an anti-inflammatory agent, an immunostimulant, a body odor-improving agent, a stool odor-improving agent, a laxative, an intestinal tract protection agent and the like can also be provided.

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains carbohydrates in an amount between 8% and 55% (w/w), proteins in an amount between 7% and 16% (w/w), lipids in an amount between 30% and 81% (w/w); and B) dietary fiber in an amount between 2 and 30 g, the food preparation being characterized by an average caloric content between 15 and 600 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with claim 1 for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasias.

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains carbohydrates in an amount between 8% and 55% (w/w), proteins in an amount between 7% and 16% (w/w), lipids in an amount between 30% and 81% (w/w); and B) dietary fiber in an amount between 2 and 30 g, the food preparation being characterized by an average caloric content between 15 and 600 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with claim 1 for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasias.

The present invention discloses a sunflower seed composition rich in pleasant prohormone and anti-depression application thereof, and belongs to the field of extraction and application of natural products. Sunflower seeds used in the composition provided by the present invention are rich in tryptophan and have a high tryptophan/neutral amino acid ratio. After defatting treatment and chlorogenic acid removal treatment, and added part can increase a glycemic index. Glucose and vitamins for promoting absorption conversion of tryptophan and ω-3 fatty acids beneficial to nervous activities enable the sunflower seeds to have a better anti-depression effect. The sunflower seed composition of the present invention can improve concentrations of a monoamine neurotransmitter (serotonin) and dopamine in the brain and has a very good effect of ameliorating and treating depression. This composition uses natural sunflower seeds as raw material and is remarkable in anti-depression effect, rich in source and free of side effects.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride; lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and fructooligosaccharides. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal tract, promoting proper gastrointestinal function, nutrient absorption, proper immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride; lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and fructooligosaccharides. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal tract, promoting proper gastrointestinal function, nutrient absorption, proper immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

This invention relates to compositions for use in the promotion of the development and/or of the growth of the surface area of the small intestine and in the associated improvement of the digestive capacity in an infant or in a young child.

This invention relates to compositions for use in the promotion of the development and/or of the growth of the surface area of the small intestine and in the associated improvement of the digestive capacity in an infant or in a young child.

The present invention relates to an oral composition with increased sweetness, and a method for manufacturing said oral composition. The present invention also relates to a concentrate for providing an oral composition, and a method for enhancing the level of sweetness of an oral composition.

According to the invention, a novel Bifidobacterial strain having an ability of assimilating two or more kinds of HMO is provided. The strain is selected from the group consisting of Bifidobacterium longum subspecies infantis (NITE BP-03068), Bifidobacterium bifidum (NITE BP-03058) and Bifidobacterium bifidum (NITE BP-03067).